m6A ‐Mediated Methylation Patterns and Their Association With Obstructive Sleep Apnea in Lung Adenocarcinoma
Cancer Reports · 2025
DOI: 10.1002/cnr2.70344 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Reports, 2025. Verfasst von Lei Xia und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory and Critical Care Medicine, The Fourth Affiliated Hospital of Soochow University, Suzhou Dushu Lake Hospital, Medical Centr…. Hauptthemen laut MEDLINE: Adenocarcinoma of Lung, Lung Neoplasms, Sleep Apnea, Obstructive, Adenosine. Die Arbeit nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Jiangsu Province Special Program of Medical Science, Suzhou Science and Technology Planning Project.
Abstract (Originalsprache)
Background
Epigenetic regulation significantly affects immune responses in lung adenocarcinoma (LUAD). However, the role of RNA N6‐methyladenosine (m6A) modification, especially in obstructive sleep apnea‐hypopnea syndrome (OSAHS) within LUAD, is not well understood.
Methods
This study examined m6A modification patterns in 973 LUAD patients using 23 regulatory genes. Unsupervised clustering categorized patients by m6A profiles, quantified by an m6A score. Associations with clinical outcomes, including survival, immune infiltration, tumor microenvironment, OSAHS incidence, and drug sensitivity, were analyzed. Results m6A regulator mutations were linked to LUAD, revealing two distinct modification patterns and three gene clusters, all tied to immune phenotypes and clinical outcomes. Higher m6A scores correlated with lower survival, more frequent OSAHS, and increased immune activity. Patients with high m6A scores were more sensitive to PD‐L1/PD‐1 inhibitors and Phenformin, while those with low scores responded better to Cisplatin, Epothilone B, and Talazoparib.
Conclusion
Analyses confirmed m6A modification's role in LUAD progression, immune regulation, and outcomes. The m6A score is a valuable prognostic marker associated with survival, OSAHS incidence, and drug sensitivity. These findings highlight m6A's potential as a therapeutic target and biomarker, particularly for LUAD patients with OSAHS.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Respiratory and Critical Care Medicine, The Fourth Affiliated Hospital of Soochow University, Suzhou Dushu Lake Hospital, Medical Centre of Soochow University, Suzhou, Jiangsu, China.
- Department of Pharmaceutical Sciences, Irma Lerma Rangel School of Pharmacy, Texas A&M University, Texas, USA.
- Department of Respiratory and Critical Care Medicine, First Affiliated Hospital of Soochow University, Suzhou, China.
ORCID-Profile: Jing Li
Förderung
- Jiangsu Province Special Program of Medical Science
- Suzhou Science and Technology Planning Project
Zitieren
APA
Xia, L., Chai, Z., Wei, X., Wei, Y., Zeng, D., Jiang, J., & Li, J. (2025). m6A ‐Mediated Methylation Patterns and Their Association With Obstructive Sleep Apnea in Lung Adenocarcinoma. Cancer Reports. https://doi.org/10.1002/cnr2.70344
Vancouver
Xia L, Chai Z, Wei X, Wei Y, Zeng D, Jiang J, et al. m6A ‐Mediated Methylation Patterns and Their Association With Obstructive Sleep Apnea in Lung Adenocarcinoma. Cancer Reports. 2025. doi:10.1002/cnr2.70344
BibTeX
@article{Xia2025,
author = {Xia, Lei and Chai, Zhuodong and Wei, Xiaoying and Wei, Yuan and Zeng, Daxiong and Jiang, Junhong and Li, Jing},
title = {m6A ‐Mediated Methylation Patterns and Their Association With Obstructive Sleep Apnea in Lung Adenocarcinoma},
journal = {Cancer Reports},
year = {2025},
doi = {10.1002/cnr2.70344}
}
EUVIMED